|
Variable
|
Control group
|
RPF group
|
P value
|
|---|
|
Number of patients
|
554
|
229
| |
|
Demographics
| | | |
|
Age (yr)
|
63.9 ± 9.2
|
63.7 ± 9.4
|
0.852
|
|
Male sex
|
431 (77.8)
|
179 (78.2)
|
0.910
|
|
Clinical characteristics
|
|
Body mass index (kg/m2)
|
24.6 ± 3.1
|
24.6 ± 3.1
|
0.706
|
|
EuroSCORE (logistic)
|
3.6 ± 3.6
|
3.5 ± 5.1
|
0.050
|
|
Medical history
|
|
Diabetes mellitus
|
263 (47.5)
|
99 (43.2)
|
0.279
|
|
Hypertension
|
365 (65.9)
|
151 (65.9)
|
0.988
|
|
Smoker, current
|
174 (31.4)
|
58 (25.3)
|
0.090
|
|
Previous myocardial infarction
|
69 (12.5)
|
43 (18.8)
|
0.022
|
|
Congestive heart failure
|
16 (2.9)
|
12 (5.2)
|
0.107
|
|
s/p PTAC c stent
|
108 (19.5)
|
50 (21.8)
|
0.458
|
|
Cerebrovascular disease
|
145 (26.2)
|
44 (19.2)
|
0.038
|
|
Peripheral vascular disease
|
61 (11.0)
|
18 (7.9)
|
0.183
|
|
eGFR <60 ml/min/1.73 m2
|
81 (14.6)
|
35 (15.3)
|
0.812
|
|
Liver disease
|
25 (4.5)
|
2 (0.9)
|
0.011
|
|
Left main coronary artery disease
|
128 (23.1)
|
48 (21.0)
|
0.513
|
|
Coronary angiography <5 days
|
177 (31.9)
|
78 (34.1)
|
0.566
|
|
Laboratory data
|
|
Hematocrit (%)
|
38.5 ± 4.8
|
38.7 ± 5.4
|
0.710
|
|
Creatinine (mg/dl)
|
1.0 ± 0.4
|
1.0 ± 0.4
|
0.469
|
|
Total bilirubin (mg/dl)
|
0.8 ± 0.3
|
0.6 ± 0.3
|
<0.001
|
|
Albumin (g/dl)
|
3.9 ± 0.4
|
3.8 ± 0.5
|
0.105
|
|
Uric acid (mg/dl)
|
5.5 ± 1.5
|
5.6 ± 1.6
|
0.745
|
|
Left ventricular ejection fraction (%)
|
56.4 ± 10.0
|
57.1 ± 10.5
|
0.165
|
|
Medication
|
|
ACEI or ARB
|
249 (44.9)
|
105 (45.9)
|
0.817
|
|
β-blocker
|
381 (68.8)
|
152 (66.4)
|
0.513
|
|
Calcium channel blocker
|
416 (75.1)
|
159 (69.4)
|
0.103
|
|
Insulin
|
127 (22.9)
|
43 (18.8)
|
0.200
|
|
Oral hypoglycemic agent
|
209 (37.7)
|
85 (37.1)
|
0.873
|
|
Statin
|
431 (77.8)
|
202 (88.2)
|
0.001
|
|
Aspirin
|
418 (75.5)
|
201 (87.8)
|
<0.001
|
|
Clopidogrel
|
298 (53.8)
|
146 (63.8)
|
0.010
|
|
Diuretics
|
104 (18.8)
|
43 (18.8)
|
0.999
|
|
Intraoperative data
|
|
Anesthesia time (min)
|
295 [267–335]
|
300 [275–340]
|
0.151
|
|
Operation time (min)
|
228 [200–267]
|
230 [200–262]
|
0.882
|
|
Grafts per patient (n)
|
3 [2–4]
|
3 [2–3]
|
0.015
|
-
RPF renal protective fluid management, EuroSCORE European System for Cardiac Operative Risk Evaluation, PTCA c stent percutaneous transluminal catheter angioplasty with stent insertion, eGFR estimated glomerular filtration rate, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
- Data are expressed as number of patients (%), mean ± standard deviation, or median [interquartile range]
